SCA


Healthy Q2 results; now all eyes on forest valuation review

28/08/19 -"After an extraordinary H2 18, performance normalisation has been picking up momentum in 2019. Yet, despite softening markets, SCA managed to attain an impressive Q2 performance. Continuation of the ..."

Pages
52
Language
English
Published on
28/08/19
You may also be interested by these reports :
04/02/26
2025 ended on a reassuring note for UPM-Kymmene, with Q4 profit ahead of consensus expectations. Even though 2025 results were restrained, management ...

04/02/26
Even though Stora’s Q4 results were soft and its turnaround is delayed, Forest division is proving to be a big and valuable differentiator. Besides ...

30/01/26
Q4 results were soft and missed street expectations. While Forest witnessed sizeable moderation, the division remained healthy and was well supported ...

30/01/26
2025 ended on a weak note, with operating profits slumping to lows unseen since 2020. While Forest had a good quarter, downward revision – even ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO